ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.24
-0.72 (-5.16%)
Jun 13, 2025, 4:08 PM HKT
-9.44%
Market Cap 5.69B
Revenue (ttm) 84.64M
Net Income (ttm) -336.12M
Shares Out 407.31M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,125,500
Average Volume 7,887,378
Open 13.96
Previous Close 13.96
Day's Range 12.78 - 14.36
52-Week Range 3.21 - 22.00
Beta n/a
RSI 63.58
Earnings Date May 26, 2025

About HKG:1541

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 156
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1541
Full Company Profile

Financial Performance

In 2024, HKG:1541's revenue was 79.54 million, an increase of 933.61% compared to the previous year's 7.70 million. Losses were -315.86 million, -16.76% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.